Wide Ranks

HRTX

Heron Therapeutics, Inc.

1.16

Top Statistics
Market Cap 176 M Forward PE -46.40 Revenue Growth 4.40 %
Current Ratio 2.28 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -20.30 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -49.83 Enterprise / Revenue 2.06 Price To Sales Trailing12 Months 1.28
Profitability
Profit Margins -20.30 % Operating Margins -13.59 %
Balance Sheet
Total Cash 70 M Total Cash Per Share 0.4660 Total Debt 178 M
Total Debt To Equity Current Ratio 2.28 Book Value Per Share -0.2640
All Measures
Short Ratio 1498.00 % Message Board Id finmb_24366 Shares Short Prior Month 30 M
City San Diego Uuid 806ac89f-8627-346c-9c83-0c9ea6a496d7 Previous Close 1.10
First Trade Date Epoch Utc 556 M Book Value -0.2640 Beta 1.81
Total Debt 178 M Volume 982549 Last Split Date 1 B
Fifty Two Week Low 1.04 Total Cash Per Share 0.4660 Total Revenue 137 M
Shares Short Previous Month Date 1 B Target Median Price 5.00 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -13.59 % Target Mean Price 6.00
Net Income To Common -27967000 Short Percent Of Float 0.2371 Implied Shares Outstanding 152 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 70 M Next Fiscal Year End 1 B
Revenue Per Share 0.9060 Held Percent Insiders 0.0071 Ebitda Margins -4.14 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.10 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.71 Open 1.09 Free Cashflow 6 M
State CA Dividend Yield 0.00 % Return On Assets -0.0231
Time Zone Short Name EST Trailing Eps -0.1600 Day Low 1.08
Address1 4242 Campus Point Court Shares Outstanding 152 M Price Hint 4
Target High Price 9.00 Website https://www.herontx.com 52 Week Change -0.0569
Average Volume 1 M Recommendation Key none Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 161.20 % Last Split Factor 1:20
Regular Market Day High 1.18 Is_sp_500 False Profit Margins -20.30 %
Fifty Two Week High 3.93 Day High 1.18 Shares Short 27 M
Regular Market Open 1.09 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 2.06 Revenue Growth 4.40 % Shares Percent Shares Out 0.1835
Operating Cashflow -8294000 Currency USD Time Zone Full Name America/New_York
Market Cap 176 M Is_nasdaq_100 False Zip 92121
Quote Type EQUITY Industry Biotechnology Long Name Heron Therapeutics, Inc.
Regular Market Day Low 1.08 Held Percent Institutions 0.8157 Current Price 1.16
Address2 Suite 200 Enterprise To Ebitda -49.83 Financial Currency USD
Current Ratio 2.28 Gross Margins 47.45 % Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 116 M
Two Hundred Day Average 2.51 Ir Website http://phx.corporate-ir.net/phoenix.zhtml?c=115565&p=irol-irhome Enterprise Value 283 M
Price To Sales Trailing12 Months 1.28 Forward PE -46.40 Regular Market Volume 982549
Ebitda -5695000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.

The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults.

The company was formerly known as A.

P.

Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.

Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.